InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 30 November 2023

This study is evaluating the effectiveness of a new targeted therapy (called HMBD-001), when given with or without chemotherapy, in people with advanced solid cancers harbouring NRG1 gene fusionsA Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions

Clinical summary

Summary

Eligible participants will be assigned to one of three Experimental Cohorts, depending on their specific cancer type.

Arm A is recruiting participants with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harbouring NRG1 gene fusions. In this cohort, participants will receive the study drug (HMBD-001) plus combination chemotherapy (nab-paclitaxel + gemcitabine). HMBD-001 will be administered intravenously weekly. Nab-paclitaxel will be administered intravenously at a dose of 125mg/m^2 on days 1, 8, and 15 every 4 weeks. Gemcitabine will be administered intravenously at a dose of 1000mg/m^2 on days 1, 8 and 15 every 4 weeks.

Arm B is recruiting participants with non-small cell lung cancer harbouring NRG1 gene fusions. In this cohort, participants will receive the study drug (HMBD-001) plus chemotherapy (docetaxel). HMBD-001 will be administered intravenously weekly. Docetaxel will be administered intravenously at a dose of 75mg/m^2 once every 3 weeks.

Arm C is recruiting participants with other solid cancers harbouring NRG1 gene fusions. In this cohort, participants will receive the study drug (HMBD-001) as monotherapy. It will be administered intravenously weekly.

 

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I/II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Hummingbird Bioscience,HMBD-001-102

Scientific Title

A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions

Eligibility

Inclusion

  • Ability to understand and be willing to sign an informed consent form

    • Males and females aged over 18 years
    • Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
    • Histologic or cytologic evidence of an advanced malignant solid that is resistant/refractory to standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the physician's judgment likely to result in clinical benefit, or the participant has demonstrated to be intolerable to such therapy, or if such therapy has been refused by the participant
    • Cancer harboring an NRG1 gene fusion with EGF-like domain; Arm A: Participants with locally advanced or metastatic pancreatic adenocarcinoma that have not received prior treatment with gemcitabine or nab-paclitaxel and /or have not received more than 2 lines of systemic therapy for advanced disease; Arm B: Participants with locally advanced or metastatic non-small cell lung cancer that have not received prior treatment with docetaxel and /or have not received more than 2 lines of systemic therapy for advanced disease; Arm C: Participants must not be eligible to participate in Arm A or B
    • Have an estimated life expectancy of at least 3 months
    • Have an archival tumour sample available or have a site of disease amenable to biopsy and be willing to undergo a biopsy prior to the receipt of the assigned study treatment
    • Have adequate organ function
    • Females must be non-pregnant and non-lactating, willing to use a highly effective method of contraception from screening until study completion or be either surgically sterile or post-menopausal
    • Males must be surgically sterile, abstinent, or if engaged in sexual relations with a woman of child-bearing potential, the participant and his partner must be surgically sterile or using an acceptable, highly effective contraceptive method from screening until study completion

Exclusion

  • Prior treatment with HMBD-001, pertuzumab, or an agent that specifically targets HER3, including pan-HER tyrosine kinase inhibitors

    • Persistent clinically significant toxicities (Grade ≥2) from previous anti-cancer therapy except for Grade >2 toxicities that are considered unlikely to put the participant at an increased risk of treatment-related toxicity and/or impact the study results e.g., alopecia
    • Most recent anti-cancer therapy including radiotherapy at least 4 weeks, or nitrosourea or mitomycin 3 at least 6 weeks, or 5 half-lives whichever is shorter prior to starting the assigned study treatment
    • Symptomatic primary Central Nervous System (CNS) cancer or metastases unless the symptoms are stable for at least 28 days prior to the first dose of the study drug and any symptoms have returned to baseline
    • Evidence of abnormal cardiac function
    • History of uncontrolled allergic reactions and/or known expected hypersensitivity to the study drugs used in the treatment arm to which the participant is to be enrolled into
    • Any other known active malignancy except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
    • Any uncontrolled illness or significant uncontrolled condition(s) requiring systemic treatment
    • Known Human Immunodeficiency Virus (HIV) infection
    • Active hepatitis B or hepatitis C infection
    • Pregnant or breast feeding
    • COVID 19 infection within 3 months prior to the first dose of the study drug
    • COVID 19 vaccination within 14 days prior to the first dose of the study drug

Inclusion

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.